Anteris raises ~$320M via public offering and Medtronic PIPE for DurAVR THV trial

Anteris Technologies Global Corp.

Public offering of 40M shares at $5.75 (including full over-allotment); gross proceeds ~$230M.
Medtronic subsidiary invests $90M via PIPE at same $5.75 price; gets board observer and participation rights.
Proceeds to fund PARADIGM pivotal trial of DurAVR THV, expand manufacturing, and v2vmedtech R&D.
Offering and PIPE expected to close Jan 22, 2026; officers/directors subject to 90-day lock-up.
Medtronic's shares subject to transfer restrictions until May 2027 and volume limits through Jan 2029.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Anteris Technologies Global Corp. entered into Underwriting Agreement with Barclays Capital Inc., Wells Fargo Securities, LLC and Cantor Fitzgerald & Co., acting as representatives of the several underwriters named therein valued at approximately $320 million (effective 2026-01-20).

Action: entry
Agreement: underwriting
Counterparty: Barclays Capital Inc., Wells Fargo Securities, LLC and Cantor Fitzgerald & Co., acting as representatives of the several underwriters named therein
Value: approximately $320 million
Effective: 2026-01-20

Exact text from the filing

On January 20, 2026, Anteris Technologies Global Corp. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Barclays Capital Inc., Wells Fargo Securities, LLC and Cantor Fitzgerald & Co., acting as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell (the “Offering”) 34,782,609 shares (the “Firm Stock”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $5.75 per share.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Anteris Technologies Global Corp. entered into Purchase Agreement with Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc valued at approximately $90.0 million (effective 2026-01-20).

Action: entry
Agreement: equity purchase
Counterparty: Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc
Value: approximately $90.0 million
Effective: 2026-01-20

Exact text from the filing

On January 20, 2026, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc (the “Investor”), pursuant to which the Company agreed to issue and sell (the “Private Placement”) to the Investor 15,652,173 shares of Common Stock of the Company (the “PIPE Shares”) at a purchase price of $5.75 per PIPE Share.

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

Anteris Technologies Global Corp. filing history →

Source: SEC EDGAR

accession 0001140361-26-001938

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.